Stay updated with breaking news from Vinod Pullarkat. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
During clinical trials, individuals treated with iptacopan had increased hemoglobin levels and did not need to receive blood transfusions.
This marks the first oral monotherapy approved for the rare blood disorder.
Iptacopan tops C5 Inhibitors for sustained hemoglobin levels, eliminating need for transfusion
Sixteen new abstracts to be presented, including the first presentation of data from the Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Phase 2/3 study that supported U.S. FDA
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that 16 new data abstracts from across its hematology/oncology development program will...